Key facts
- Psy Therapeutics’s last known valuation is $21.5M (Oct 2019).
- It has raised $13.2M across 2 recorded rounds; the latest was Early Stage VC ($6.8M) in Dec 2021.
- Notable investors include Ayuh Ventures, JLS Fund, Palo Santo, WPSS.bio.
- Psy Therapeutics has filed 5 Form Ds with the SEC since 2019, most recently Sep 2025 ($6.8M sold to 23 investors).
- Status: Privately Held (backing).
Investors
4- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Psy Therapeutics
Funding rounds
2 roundsAbout Psy Therapeutics
Developer of novel small molecule therapies designed to treat central nervous system disorders such as pain, Parkinson's disease, and PTSD (Post-traumatic stress disorder). The company offers brain-penetrant, well-tolerated drug candidates based on a chemistry-driven, de-risked approach, enabling patients affected by serious neurological conditions to access more effective and better-tolerated treatments.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2016
- Website
- psythx.com/
- Ownership
- Privately Held (backing)
Psy Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Psy Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Psy Therapeutics in its N-PORT filings yet. We sweep new filings monthly.